Unravelling the mechanisms of aducanumab on efficacy of Aß clearance by iPSC‐derived human microglia in 2D and 3D cell cultures
Ada J Lin, Stefan Wendt, Declan Brennan, Haakon B Nygaard · 2025
Read Unravelling the mechanisms of aducanumab on efficacy of Aß clearance by iPSC‐derived human microglia in 2D and 3D cell cultures by Ada J Lin, Stefan Wendt, Declan Brennan, Haakon B Nygaard (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11710236.txt.
Description
Ada J Lin and co-authors present a 2025 conference abstract on how an Alzheimer's antibody drug helps clear amyloid. The drug, aducanumab, was the first of its kind to win limited approval, in 2021. The team grew human microglia, the brain's immune cells, from stem cells and watched them work in flat cultures and in small balls of brain tissue.
In flat cultures, the drug made microglia swallow amyloid faster and in larger amounts. It also cut the share of dense, clumped amyloid inside the cells. In the tissue balls, the drug did not lower total amyloid but blocked larger clumps from forming, which may aid later clearance.
Catalog record
| CREATOR | Ada J Lin, Stefan Wendt, Declan Brennan, Haakon B Nygaard |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 2 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |